Onconetix, Inc. (ONCO)
- Previous Close
0.1111 - Open
0.1086 - Bid --
- Ask --
- Day's Range
0.1052 - 0.1134 - 52 Week Range
0.1000 - 1.5800 - Volume
376,115 - Avg. Volume
368,237 - Market Cap (intraday)
2.532M - Beta (5Y Monthly) 3.35
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
onconetix.gcs-web.comRecent News: ONCO
Performance Overview: ONCO
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCO
Valuation Measures
Market Cap
2.53M
Enterprise Value
7.86M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
33.19
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.44%
Return on Equity (ttm)
-314.47%
Revenue (ttm)
58.47k
Net Income Avi to Common (ttm)
-37.41M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
4.55M
Total Debt/Equity (mrq)
703.88%
Levered Free Cash Flow (ttm)
-16.09M
Research Analysis: ONCO
Company Insights: ONCO
ONCO does not have Company Insights